Phospho-SCNN1B (T615) Antibody

What is the specificity of Phospho-SCNN1B (T615) Antibody and how is it validated?

The Phospho-SCNN1B (T615) Antibody is a rabbit polyclonal antibody that specifically recognizes SCNN1B (epithelial sodium channel beta subunit) when phosphorylated at threonine 615. This antibody is generated using a synthesized phosphopeptide derived from human SCNN1B around the phosphorylation site of T615, with the immunogen typically encompassing amino acids 581-630 .

The specificity of this antibody is rigorously validated through several methods:

• Peptide competition assays where pre-incubation with the immunizing phosphopeptide blocks antibody binding

• Western blot analysis showing a single band at the expected molecular weight (~73 kDa)

• Immunohistochemistry and immunofluorescence showing localization consistent with known SCNN1B distribution patterns

• Comparative analysis with non-phosphorylated samples or phosphatase-treated controls

These validation experiments provide critical evidence that the antibody specifically detects the phosphorylated form of SCNN1B without cross-reactivity to non-phosphorylated SCNN1B or other phosphorylated proteins.

What is the biological significance of SCNN1B phosphorylation at T615?

Phosphorylation at T615 represents an important regulatory mechanism for SCNN1B function. The epithelial sodium channel (ENaC) plays essential roles in:

• Electrolyte and blood pressure homeostasis

• Airway surface liquid homeostasis for proper mucus clearance

• Reabsorption of sodium in kidney, colon, lung, and sweat glands

• Taste perception

Phosphorylation at T615 can modulate these functions by affecting:

• Channel gating properties and ion conductance

• Channel trafficking to and from the cell membrane

• Protein-protein interactions with regulatory molecules

• Stability and turnover of the channel complex

Recent research has also identified SCNN1B as a tumor suppressor in colorectal cancer, functioning as a c-Raf antagonist that suppresses oncogenic MEK-ERK signaling . The phosphorylation status at T615 may influence this tumor suppressor activity, representing a critical area for ongoing investigation.

What applications is this antibody validated for and what are the recommended dilutions?

The Phospho-SCNN1B (T615) Antibody has been validated for multiple research applications with the following recommended dilution ranges:

These dilutions provide starting points for optimization in specific experimental contexts . The antibody has been confirmed to react with human, mouse, and rat samples across these applications, with some antibodies also reactive to African green monkey samples .

How should samples be prepared to preserve SCNN1B phosphorylation status?

Preserving phosphorylation status is critical when working with phospho-specific antibodies. For optimal detection of phosphorylated SCNN1B at T615, implement these methodological approaches:

For protein extraction:

• Harvest tissues or cells quickly and proceed immediately to lysis

• Use ice-cold lysis buffers containing both protease inhibitors and phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate)

• Maintain samples at 4°C throughout processing

• Avoid repeated freeze-thaw cycles of lysates

For tissue sections:

• Fix tissues promptly after collection (4% paraformaldehyde is recommended)

• For IHC, perform heat-induced antigen retrieval with Tris-EDTA buffer at pH 8.0

• Apply high-pressure and high-temperature antigen retrieval methods for optimal phospho-epitope exposure

• Block endogenous phosphatases during staining procedures

For cell cultures:

• Consider direct lysis in hot SDS sample buffer for immediate denaturation and phosphatase inactivation

• For immunofluorescence, brief fixation with 4% paraformaldehyde is typically sufficient

These methodological considerations ensure that the phosphorylation state of SCNN1B at T615 is accurately preserved for subsequent analysis.

What controls should be incorporated when using Phospho-SCNN1B (T615) Antibody?

Implementing appropriate controls is essential for accurate interpretation of results with Phospho-SCNN1B (T615) Antibody:

Primary controls:

• Blocking peptide control: Pre-incubate antibody with the immunizing phosphopeptide (the search results show this is commonly used for validation). This control demonstrates specificity by showing reduced or eliminated signal when the antibody's binding site is occupied .

• Phosphatase treatment control: Treat a portion of the positive sample with lambda phosphatase to remove phosphorylation. This confirms the phospho-specificity of the signal.

• Positive tissue control: Use tissues known to express phosphorylated SCNN1B (kidney, lung, colon) as positive controls .

• Negative tissue control: Include tissues known to have minimal SCNN1B expression or samples from knockdown/knockout models.

Secondary controls:

• Loading controls: For Western blot, include appropriate loading controls (β-actin, GAPDH) or total protein staining.

• Secondary antibody-only control: Omit primary antibody to identify any non-specific binding from the secondary antibody.

• Total SCNN1B control: When possible, parallel analysis with an antibody detecting total SCNN1B (regardless of phosphorylation) helps determine whether observed changes reflect altered phosphorylation or total protein levels .

These methodological controls ensure reliable data interpretation and help troubleshoot potential experimental issues.

How can blocking peptides be effectively used to validate antibody specificity?

Blocking peptides represent a powerful methodological approach for validating phospho-specific antibody specificity. For Phospho-SCNN1B (T615) Antibody, this approach involves:

• Experimental setup:

  • Divide your samples into two equal portions

  • Pre-incubate the antibody with excess immunizing phosphopeptide (5-10 μg peptide per 1 μg antibody) for 1-2 hours at room temperature

  • In parallel, prepare the regular antibody dilution without peptide

  • Process identical samples with both antibody preparations

• Implementation across applications:

  • For Western blot: Run duplicate lanes of the same samples, probing with blocked and unblocked antibody

  • For IHC/IF: Process consecutive sections with blocked and unblocked antibody

  • For ELISA: Include blocked antibody wells as additional controls

• Result interpretation:

  • Specific binding will be significantly reduced or eliminated in samples incubated with the antibody-peptide complex

  • Non-specific binding will remain largely unchanged

  • The differential pattern confirms specificity for the phosphorylated epitope

The search results show multiple examples where blocking peptide controls demonstrated clear abrogation of signal in Western blot, IHC, and IF applications, confirming the specificity of the Phospho-SCNN1B (T615) Antibody for its target epitope.

How should phospho-SCNN1B expression levels be quantified and normalized?

Accurate quantification of phospho-SCNN1B levels requires rigorous methodological approaches to normalization:

These methodological approaches ensure reliable quantification of SCNN1B phosphorylation status across experimental conditions.

What are common challenges in Western blot analysis with this antibody and how can they be resolved?

When performing Western blot analysis with Phospho-SCNN1B (T615) Antibody, researchers may encounter several methodological challenges:

• Weak or absent signal:

  • Increase protein loading (50-80 μg per lane)

  • Reduce antibody dilution (try 1:500 instead of 1:2000)

  • Extend primary antibody incubation to overnight at 4°C

  • Verify sample preparation includes phosphatase inhibitors

  • Consider using PVDF membranes which retain more protein than nitrocellulose

  • Implement enhanced chemiluminescence detection systems

• High background:

  • Increase blocking time or concentration (5% BSA in TBST for 2 hours)

  • Use more stringent washing (0.1% Tween-20, additional wash steps)

  • Dilute primary and secondary antibodies further

  • Pre-absorb antibody with BSA to reduce non-specific interactions

• Multiple bands:

  • Verify if bands represent different isoforms, post-translational modifications, or degradation products

  • Include phosphatase-treated controls to confirm phospho-specificity

  • Add protease inhibitors to prevent degradation

  • Use gradient gels for better resolution of closely migrating bands

• Inconsistent results:

  • Standardize lysate preparation with precise protocols

  • Aliquot antibodies to avoid freeze-thaw cycles

  • Include the same positive control in each experiment

  • Maintain consistent transfer conditions and blocking protocols

These methodological approaches can significantly improve Western blot results when working with Phospho-SCNN1B (T615) Antibody.

How can Phospho-SCNN1B (T615) Antibody be used to investigate ENaC regulation in hypertension and kidney disease?

The Phospho-SCNN1B (T615) Antibody provides valuable methodological approaches for investigating ENaC regulation in hypertension and kidney disease:

• Expression profiling in disease models:

  • Compare phospho-SCNN1B levels between normotensive and hypertensive animal models

  • Analyze kidney biopsies from patients with various forms of hypertension or salt-sensitive disorders

  • Correlate phosphorylation patterns with disease severity and treatment response

• Regulation by the renin-angiotensin-aldosterone system:

  • Examine T615 phosphorylation changes in response to aldosterone stimulation

  • Investigate how angiotensin II signaling affects SCNN1B phosphorylation

  • Monitor phosphorylation status during treatment with ACE inhibitors or ARBs

• Sodium handling studies:

  • Track phospho-SCNN1B levels during dietary sodium manipulation

  • Compare salt-sensitive versus salt-resistant models

  • Correlate phosphorylation with functional measurements of sodium transport

• Therapeutic target identification:

  • Screen for compounds that modulate T615 phosphorylation

  • Evaluate whether existing diuretics (amiloride, triamterene) affect phosphorylation status

  • Develop phosphorylation-specific modulators as potential new therapeutics

• Liddle syndrome investigations:

  • The search results indicate Liddle syndrome results from mutations affecting SCNN1B degradation

  • Investigate whether T615 phosphorylation influences the phenotypic expression of Liddle mutations

  • Examine interaction between phosphorylation and the PY motif recognized by Nedd4-2

These methodological approaches can provide significant insights into the role of SCNN1B phosphorylation in blood pressure regulation and kidney function.

What is the relationship between SCNN1B phosphorylation and the MAPK signaling pathway?

Recent research has revealed an intriguing relationship between SCNN1B and MAPK signaling that can be further investigated using Phospho-SCNN1B (T615) Antibody:

• Tumor suppressor function:

  • The search results indicate SCNN1B functions as a tumor suppressor in colorectal cancer by suppressing MAPK signaling

  • SCNN1B overexpression suppressed p-MEK/p-ERK expression and SRE-mediated transcription activities

  • This confirmed blockade of the Ras-Raf-MEK-ERK cascade

• Mechanistic interactions:

  • SCNN1B impairs activation of c-Raf by inducing its inhibitory phosphorylation

  • It also targets active c-Raf for degradation

  • These mechanisms were confirmed when ectopic expression of c-Raf rescued cell proliferation in SCNN1B-overexpressing CRC cells

• Methodological approaches to investigate this relationship:

  • Use phospho-specific antibodies for both SCNN1B (T615) and components of the MAPK pathway (e.g., Phospho-ERK1/2 (Thr202/Tyr204) as referenced in the search results)

  • Perform co-immunoprecipitation studies to identify phosphorylation-dependent protein interactions

  • Conduct parallel phosphorylation analysis in response to MAPK pathway inhibitors

• Experimental validation:

  • Create phospho-mimetic (T615D/E) and phospho-deficient (T615A) SCNN1B mutants

  • Examine their effects on MAPK pathway activation

  • Determine whether T615 phosphorylation status affects SCNN1B's ability to regulate c-Raf

• Translational implications:

  • Investigate whether phospho-SCNN1B status could serve as a biomarker in cancers with hyperactivated MAPK signaling

  • Explore combined targeting of SCNN1B and MAPK pathway components in cancer therapy

This research direction represents a significant opportunity to understand how sodium channel regulation intersects with one of the most important signaling pathways in cell proliferation and differentiation.

How does SCNN1B phosphorylation impact its tumor suppressor function in colorectal cancer?

The search results identify SCNN1B as a tumor suppressor in colorectal cancer, opening important research questions about how phosphorylation at T615 might influence this function:

• Expression patterns in cancer progression:

  • The search results show SCNN1B mRNA and protein expression were down-regulated in primary CRC and CRC cells

  • In a tissue microarray cohort (N = 153), SCNN1B protein was an independent prognostic factor for favorable outcomes in CRC

  • Phospho-SCNN1B (T615) Antibody can be used to determine whether phosphorylation status correlates with these prognostic outcomes

• Functional consequences:

  • Ectopic expression of SCNN1B in CRC cell lines suppressed cell proliferation, induced apoptosis and cell cycle arrest, and suppressed cell migration in vitro

  • Xenograft models validated the tumor suppressive function of SCNN1B in vivo

  • Research could investigate whether these effects depend on the phosphorylation status at T615

• Methodological approaches:

  • Use site-directed mutagenesis to create T615 phospho-mimetic and phospho-deficient mutants

  • Compare their effects on:

    • Cell proliferation and colony formation

    • Apoptosis induction

    • Cell cycle regulation

    • Migration and invasion capacity

    • Tumor formation in xenograft models

• Mechanistic studies:

  • Investigate whether T615 phosphorylation affects SCNN1B's ability to:

    • Induce inhibitory phosphorylation of c-Raf

    • Target active c-Raf for degradation

    • Block the Ras-Raf-MEK-ERK cascade

  • Determine if phosphorylation alters SCNN1B's subcellular localization or protein-protein interactions

• Clinical correlations:

  • Assess T615 phosphorylation status in patient samples using the Phospho-SCNN1B (T615) Antibody

  • Correlate with treatment response, particularly to therapies targeting MAPK signaling

  • Evaluate potential as a predictive biomarker

This research could provide valuable insights into the molecular mechanisms underlying SCNN1B's tumor suppressor function and potentially identify new therapeutic strategies for colorectal cancer.

What techniques can be combined with phospho-specific antibodies for comprehensive analysis of SCNN1B regulation?

For comprehensive analysis of SCNN1B regulation, Phospho-SCNN1B (T615) Antibody can be integrated with multiple complementary techniques:

• Multi-omics approaches:

  • Phosphoproteomics to identify all phosphorylation sites on SCNN1B and co-regulated proteins

  • RNA-seq to correlate phosphorylation with transcriptional changes

  • ChIP-seq to investigate transcriptional regulation of SCNN1B

  • Interactomics to identify phosphorylation-dependent protein-protein interactions

• Advanced microscopy techniques:

  • Super-resolution microscopy to visualize nanoscale distribution of phosphorylated SCNN1B

  • FRET/FLIM to detect conformational changes induced by phosphorylation

  • Live-cell imaging with phospho-sensors to monitor dynamic phosphorylation events

  • Correlative light and electron microscopy to link phosphorylation to ultrastructural features

• Functional assays:

  • Electrophysiology to directly measure channel activity correlated with phosphorylation status

  • Surface biotinylation to quantify membrane expression of phosphorylated channels

  • FACS analysis to isolate cell populations based on phosphorylation status

  • Single-molecule tracking to study how phosphorylation affects channel dynamics

• In vivo approaches:

  • Generate knock-in models with phospho-mimetic or phospho-deficient mutations

  • Use intravital microscopy combined with phospho-specific antibodies

  • Develop tissue-specific expression of phosphorylation site mutants

  • Apply optogenetic or chemogenetic tools to manipulate kinases/phosphatases in vivo

• Computational methods:

  • Molecular dynamics simulations to predict structural changes induced by phosphorylation

  • Systems biology modeling of phosphorylation networks

  • Machine learning approaches to identify patterns in phosphorylation data

  • Pathway analysis to contextualize phosphorylation within broader signaling networks

Integrating these methodological approaches with phospho-specific antibody techniques provides a comprehensive understanding of how SCNN1B phosphorylation regulates channel function in both physiological and pathological contexts.